Charles Schwab
BNTC icon

Charles Schwab’s Benitec Biopharma BNTC Stock Holding History

Charles Schwab’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$654K Buy
61,411
+16,137
+36% +$187K ﹤0.01% 3025
2025
Q4 		$610K Hold
45,274
– – ﹤0.01% 3098
2025
Q3 		$635K Hold
45,274
– – ﹤0.01% 3097
2025
Q2 		$530K Buy
+45,274
New +$633K ﹤0.01% 3119

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Charles Schwab's BNTC Position: Q1 2026 in Review

Charles Schwab increased its Benitec Biopharma (BNTC) stake by 36% in Q1 2026, buying an estimated $187K and bringing the position to 61,411 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Charles Schwab first reported a position in BNTC in Q2 2025 and has held it in 4 quarters since. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Charles Schwab held 61,411 shares of Benitec Biopharma worth $654K as of Q1 2026.
  • Charles Schwab bought 16,137 Benitec Biopharma shares in Q1 2026, an estimated $187K.
  • Benitec Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3025 holding.
  • Charles Schwab first reported a position in Benitec Biopharma in Q2 2025 and has held it in 4 quarters since.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.